Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1301 to 1310 of 2733 total matches.
PSA Reconsidered
The Medical Letter on Drugs and Therapeutics • Aug 06, 2012 (Issue 1396)
and treatments.1
SOME EXPERTS DISAGREE — In the same issue of
the same journal, an ad hoc group of urologists ...
Three recent publications have focused attention once
more on the contentious question of whether men
should be screened for prostate cancer by measuring
serum concentrations of prostate specific antigen (PSA).
In Brief: Two New Seasonal Influenza Vaccines
The Medical Letter on Drugs and Therapeutics • Feb 04, 2013 (Issue 1409)
years IM/0.5 mL 18.25
(Novartis) syringe2
1. Approximate cost of a single dose according ...
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is...
In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015 (Issue 1480)
1480) October 26, 2015
Published by The Medical Letter, Inc. • A Nonprofit Organization
Table 1 ...
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta2-agonist dry powder inhaler available in the US.Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which...
In Brief: Jadenu - A New Formulation of Deferasirox for Iron Overload (online only)
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
of
deferasirox (Exjade) was approved in 2005 for the same
indications.1 Jadenu and Exjade are the only once ...
The FDA has approved an oral tablet formulation of deferasirox (Jadenu [ jade' new] – Novartis) for once-daily treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients ≥2 years old or chronic iron overload in patients ≥10 years old with non-transfusion-dependent thalassemia syndromes. A once-daily, oral tablet for suspension formulation of deferasirox (Exjade) was approved in 2005 for the same indications.1 Jadenu and Exjade are the only once-daily oral formulations for iron chelation available in the US.No new clinical trials were required...
In Brief: Repatha Pushtronex - A New Evolocumab Injection Device
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016 (Issue 1503)
syringes and autoinjectors (Repatha Sureclick).1 Use of these
formulations to administer the once-monthly ...
The PCSK9 inhibitor evolocumab (Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C), and as an adjunct to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH).Evolocumab is also...
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first.1 A third oral ...
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos – Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn's disease of the ileum and/or ascending colon in
patients ≥8 years old and for maintenance of remission
for up to 3 months in adults. Ortikos is the second oral
formulation of budesonide to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first. A third oral formulation of budesonide
(Uceris) is approved for induction of remission in
patients with mild to moderate active ulcerative...
Comparison Chart: Some Non-Statin Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Jun 08, 2026 (Issue 1756)
Lerodalcibep – Lerochol (Lib Therapeutics)
300 mg/1.2 mL single-use prefilled pens 300 mg SC once/month 55–60 ...
View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs
Med Lett Drugs Ther. 2026 Jun 8;68(1756):e96-8 doi:10.58347/tml.2026.1756c | Show Introduction Hide Introduction
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2025 (Issue 1736)
Volume 67 September 1, 2025
Drugs for ADHD
Attention-deficit/hyperactivity disorder (ADHD ...
Attention-deficit/hyperactivity disorder (ADHD) is a
common chronic neurodevelopmental disorder often
diagnosed in school-age children that frequently
persists into adulthood.Pharmacologic treatment
of ADHD has been associated with reduced risks of
substance abuse, criminal behavior, unintentional
injuries, serious traffic accidents, and all-cause
mortality. Drugs approved by the FDA for treatment
of ADHD are listed in Table 1.
Med Lett Drugs Ther. 2025 Sep 1;67(1736):137-44 doi:10.58347/tml.2025.1736a | Show Introduction Hide Introduction
Drugs for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Jun 08, 2026 (Issue 1756)
the lifetime risk of
atherosclerotic cardiovascular disease (ASCVD) and death.1
LIPOPROTEIN GOALS ...
Recently published multisociety guidelines for the
management of dyslipidemia emphasize early identification
and treatment of dyslipidemia to reduce the lifetime risk of
atherosclerotic cardiovascular disease (ASCVD) and death.
Med Lett Drugs Ther. 2026 Jun 8;68(1756):89-95 doi:10.58347/tml.2026.1756a | Show Introduction Hide Introduction
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
90 mcg/inh
90 mcg/inh
0.63, 1.25, 2.5 mg/3 mL soln
HFA MDI (200 inh/unit)
HFA MDI (60, 200 inh ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction
